Aleagha, Omid EmamiMoeinzadeh, ForouzanShokouh, Seyedeh Farnaz MoeiniDogan, ErkanSadeghi, Masoud2024-09-292024-09-2920212392-10992449-8238https://doi.org/10.5114/ceh.2021.109424https://hdl.handle.net/20.500.14619/7686Aim of the study: We reported the association between interleukin 8 (IL-8) polymorphisms (-251T/A and +781C/T) and hepatocellular carcinoma (HCC) risk in a meta-analysis. Material and methods: Scopus, PubMed, Web of Science, and Cochrane Library databases were searched until 21 November 2021. The analyses were performed by RevMan 5.3 software using odds ratios (ORs) and 95% confidence intervals (Cis). Also, the analysis of publication bias was performed by CMA 2.0 software. Results: Searching databases/sources, five articles including ten studies were entered into the meta-analysis. The pooled ORs for -251T/A polymorphism were 1.07 (p = 0.55), 1.04 (p = 0.75), 1.31 (p = 0.24), 1.24 (p = 0.31), and 1.85 (p = 0.29) for allele, homozygote, heterozygote, recessive and dominant models, respectively. With regards to +781C/Tpolymorphism, the pooled ORs were 0.74 (p = 0.07), 0.53 (p = 0.03), 0.83 (p = 0.41), 0.75 (p = 0.19), and 0.57 (p = 0.02) for allele, homozygote, heterozygote, recessive, and dominant models, respectively. Conclusions: The findings of the meta-analysis showed a lack of significant association between IL-8 (-251T/A) polymorphism and the HCC risk, whereas the TT genotype of IL-8 (+781C/T) polymorphism had a protective role in HCC.eninfo:eu-repo/semantics/openAccesshepatocellular carcinomainterleukin 8liver cancerpolymorphismArticle10.5114/ceh.2021.1094242-s2.0-85116993369285334712829Q32787WOS:000724731900005N/A